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ABSTRACT. Objective. To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the
treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU).
Methods. Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by
a standard protocol and data were entered into the National Italian Registry (NIR). At baseline, all
patients were refractory to standard immunosuppressive treatment and/or were cortico -
steroid-dependent. Data recorded every 3 months included uveitis course, number/type of ocular
complications, drug-related adverse events (AE), treatment change or withdrawal, and laboratory
measures. Data of patients treated for at least 1 year were retrieved from the NIR and analyzed using
descriptive statistics. Treatment efficacy was based on change in uveitis course and in number of
ocular  complications.
Results. Up to December 2009, data for 108 patients with JIA-AU treated with anti-tumor necrosis
factor-agents were recorded in the NIR and data from 91, with at least 12 months’ followup, were
included in the study. Forty-eight patients were treated with IFX, 43 with ADA. Forty-seven patients
(55.3%) achieved remission of AU, 28 (32.9%) had recurrent AU, and 10 (11.8%) maintained a
chronic course. A higher remission rate was observed with ADA (67.4% vs 42.8% with IFX; p =
0.025). Ocular complications decreased from 0.47 to 0.32 per subject. Five patients experienced
resolution of structural complications. No patient reported serious AE; 8 (8.8%) experienced 11
minor AE (9 with IFX, 2 with ADA).
Conclusion. IFX and ADA appear to be effective and safe for treatment of refractory JIA-related
uveitis, with a better performance of ADA in the medium-term period. (First Release Nov 1 2012; 
J Rheumatol 2013;40:74–9; doi:10.3899/jrheum.120583)
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Anterior uveitis (AU) is the most important extraarticular
complication of juvenile idiopathic arthritis (JIA) and may
lead to severe visual impairment due to sight-threatening
complications such as posterior synechiae, band kerato -
pathy, cataract, and glaucoma1. Although treatment of AU is
not standardized, it is increasingly evident that early
aggressive therapy is needed to prevent irreversible compli-
cations and preserve visual function.
The introduction of anti-tumor necrosis factor-α
(anti-TNF-α) agents has significantly changed the
management of many rheumatic conditions, including AU,
but experience to date is still limited. Since January 2007 the
Italian National Agency for Drugs has approved the use of
the anti-TNF-α agents infliximab (IFX) and adalimumab
(ADA) as off-label treatment for refractory JIA-related
uveitis. Because of the lack of information on the longterm
safety and efficacy of these new agents, a National Italian
Registry (NIR) was established and data were prospectively
collected to periodically update the health authorities. We
report the data retrieved from the registry on the safety and
efficacy of IFX and ADA in patients treated for at least 1
year.
MATERIALS AND METHODS
Patients with JIA-related uveitis treated with the anti-TNF-α agents IFX
and ADA and followed since January 2007 at pediatric rheumatology and
ophthalmologic institutions in Italy were managed by a standardized
protocol and data were prospectively collected in the NIR. All patients were
diagnosed as having JIA according to the International League of
Associations for Rheumatology criteria2 and AU according to the SUN
Working Group criteria3.
For treatment, all participating centers adopted a “stepladder”
algorithm. New-onset uveitis was treated just with mydriatics and/or
topical corticosteroid therapy. In case of recurrent or persistent AU, a brief
course (1–2 months) of systemic corticosteroids (oral prednisone 0.5–1
mg/kg/day) was prescribed. Immunosuppressive treatment [methotrexate
(MTX) 10–15 mg/m2/week or cyclosporine A (CYA) 3–5 mg/kg/day] was
used in cases of refractory or steroid-dependent AU. Finally, anti-TNF
agents were considered for patients refractory to MTX or CYA. 
The indications to start anti-TNF treatment were intolerance or non -
responsiveness to at least 6 months of MTX and/or CYA treatment, and/or
oral prednisone dependency.
The anti-TNF-α agents IFX or ADA were administered according to the
Italian National Health System regulations. Intravenous IFX infusions,
dosage 5 mg/kg, were scheduled at 0, 2, 6, and 12 weeks and then
continued every 6–8 weeks; ADA was administered subcutaneously every
2 weeks at a dosage of 1 mg/kg (maximum 40 mg). In patients refractory
to treatment, shorter IFX infusion intervals were tried (maximum every 4
weeks). In patients receiving ADA, the dose was progressively increased to
a maximum 40 mg.
Consecutive ophthalmologic evaluations were performed at at least
3-month intervals. Data collected were uveitis disease course, number and
type of ocular complications, drug-related adverse events (AE), causes of
treatment change or withdrawal, and laboratory measurements.
Concomitant use of topical and systemic corticosteroids and systemic
immunosuppressive agents was documented. Sparing of topical and
systemic corticosteroid and immunosuppressive drugs during anti-TNF
treatment was recorded.
The uveitis disease course was defined according to the SUN Working
Group criteria3. Chronic (severe) uveitis was considered the presence of
persistent or unremitting uveitis or a uveitis relapse every 3 months or less,
or the presence of at least 3 relapses/year. Recurrent (moderate) uveitis was
considered when repeated flares of AU were separated by periods of
inactivity longer than 3 months’ duration or when there were fewer than 3
relapses/year.
Clinical remission on medication was defined as the absence of active
uveitis for more than 6 months on systemic treatment and with no or
minimal topical treatment (corticosteroid and/or mydriatic-cycloplegic
eyedrops used less than once daily). 
Uveitis flare was defined as an increase of the cells in the anterior
chamber of 2+ or more compared to baseline3. Ocular complications were
recorded at baseline, at start of treatment, and then during each followup
visit. Ocular hypertension was diagnosed in patients in whom the
intraocular pressure (IOP) had been > 22 mm Hg for > 3 months, or a single
IOP measurement was > 30 mm Hg4.
Patients were monitored for AE, vital signs, and laboratory assessments
at each study visit. Serious AE, defined as those requiring hospitalization,
and changes in vital signs for a minimum of 1 h from the start of each
anti-TNF administration, were recorded. As recommended, Quantiferon TB
Gold test screening was performed before initiation of the treatment TNF
inhibitors and at least yearly during the followup5.
Laboratory monitoring included white blood cell (WBC) count,
hemoglobin, platelet count, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), alanine transaminase (ALT), aspartate trans -
aminase (AST), creatinine, blood urea nitrogen (BUN), and urinalysis. ESR
and CRP were considered abnormal if > 35 mm/h and 0.5 mg/dl, respec-
tively. WBC counts and hemoglobin were considered abnormal if greater or
less than 2 SD values for age. Platelet count was considered abnormal if >
400 × 103/mm3 or < 150 × 103/mm3. ALT and AST were considered
abnormal if > 40 U/l, creatinine if > 62 µmol/l or 0.47 mg/dl, and BUN if
> 6.40 mmol/l. Antinuclear antibodies, tested by immunofluorescence on
Hep2 cell line, were considered positive with a titer > 1:80. Anti-dsDNA
and extractable nuclear antigen were considered positive or abnormal
according to the standard value of the laboratory of each participating
center. Tests were performed at baseline and then every 3 months during the
followup and were concomitant with the clinical assessment. Any treatment
change or withdrawal was also recorded.
Statistical analysis. Data for patients treated with anti-TNF agents for at
least 1 year were retrieved anonymously from the NIR and analyzed by
descriptive statistics. A comparative analysis on safety and efficacy of IFX
and ADA was performed. Patients undergoing a treatment change from IFX
to ADA or vice versa were excluded from the efficacy analysis but included
in that for safety. All significance tests were 2-sided and p values < 0.05
were considered significant. All analyses were performed using StatsDirect
(version 2.7.5, StatsDirect Ltd.). 
RESULTS
During the period January 2007-December 2009, 108
patients with JIA-AU were included in the NIR, and 91 (71
female, 20 male) with at least 12 months of followup
entered our study. Clinical characteristics of the patients are
summarized in Table 1. The mean age at start of treatment
was 9.7 years and the duration of uveitis was 4.9 years. The
mean followup duration after treatment start was 1.5 years
(range 1–3 yrs). The mean age at arthritis onset was 4.5
years, while the mean age at uveitis onset was 4.9 years.
According to the diagnostic criteria for JIA of the
International League of Associations for Rheumatology2,
90.2% had persistent and 9.8% extended oligoarticular JIA.
All patients had failed previous immunosuppressive
 treatments (MTX, CYA) and/or were dependent on oral
 corticosteroids.
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Forty-three patients were initially treated with ADA, 48
with IFX. Comparison of the 2 groups at baseline showed no
significant differences (Table 1). Seventy-five patients
(83.5%) were receiving MTX at baseline and 58 (63.7%)
continued the treatment afterward (p < 0.001). CYA-treated
patients also decreased in number, from 13 (14.3%) at
baseline to 7 (7.7%) during anti-TNF therapy (p < 0.05). Of
35 patients (38.5%) taking prednisone at baseline, 16
(17.6%) were able to discontinue it during the study period.
Indeed, for those who were still taking immunosuppressive
treatment at the end of the yearly observation period, the
mean dosage of drugs could be gradually tapered as follows:
MTX from 10.2 to 8.8 mg/m2/week, CYA from 3.4 to 2.6
mg/kg/day, and prednisone from 0.52 to 0.11 mg/kg/day
(mean values). Topical corticosteroid eyedrops could be
discontinued in 38 patients and tapered in 53. None of the
patients received subtenon or intravitreal corticosteroid
injection.
During the first year of treatment, 6 patients (6.6%), all
receiving IFX, changed therapy: in 3, IFX was interrupted
because of infusion reactions, in the remainder because of
diminished tolerance or compliance. All were shifted to
ADA, after a mean 7.4 months (range 3.3–10.3 mo) from
the start of treatment. No patient changed from ADA to IFX.
For the course of uveitis, 47 patients (55.3%) achieved
remission, 28 (32.9%) had recurrent uveitis, and 10 (11.8%)
maintained a chronic disease course (Table 2). A significant
difference between IFX and ADA treatment was observed,
with a better remission rate for ADA (67.4% vs 42.8% for
IFX; p = 0.025). Among 29 patients with a recurrent uveitis
course at treatment start, 17 (58.6%) achieved remission and
12 (41.4%) remained stable. Among 56 patients with a
chronic uveitis course at baseline, 82.2% improved signifi-
cantly: 30 patients (53.6%) achieved remission, 16 (28.6%)
had a reduced rate of uveitis flares (recurrent course), and
only 10 (17.8%) maintained a chronic disease course.
At treatment start, 23 patients (27.1%) showed 40 ocular
complications (Figure 1), which were multiple in 12
(14.1%). Cataract was present in 17 subjects (20.0%),
vitreitis in 12 (14.1%), cystoid macular edema [CME,
confirmed by optical coherence tomography (OCT)] in 6
(7.1%), and ocular hypertension in 5 (5.9%). As absolute
values, complications decreased from 40 (0.47 per subject)
to 27 (0.32 per subject), with 32% improvement. Five
patients experienced complete resolution of structural
complications. In 2 of them it was achieved in combination
with a cataract surgery procedure. In particular, the cataract
surgery was possible only because of the prior achievement
of remission of inflammation due to anti-TNF treatment.
Therefore, the successful result should be attributed to both
medical and surgical interventions. Of 62 patients without
complications at treatment start, only 3 (4.8%) developed a
new cataract. Two of them were receiving IFX, and 1 ADA.
Considering changes of structural complications, no signif-
icant difference between the 2 anti-TNF-α agents was
observed.
During treatment, no patient reported serious or
life-threatening AE. Eight (8.8%) experienced 11 minor AE
(12.1 per 100 patient/yrs; Table 3). Nine AE were related to
IFX treatment (18.8 per 100 patient/yrs) and 2 to ADA (4.7
per 100 patient/yrs).
No significant laboratory changes related to anti-TNF
agents were observed and no significant differences were
found comparing IFX and ADA. Analysis of autoantibodies
showed that the percentage of patients with positive anti -
nuclear antibody tests decreased from 29.7% to 14.3%
during followup, while 3 subjects were found to have
positive anti-dsDNA antibody results at low titer. Two were
receiving IFX and 1 ADA. However, these findings were not
associated with features of lupus-like syndrome.
Table 1. Baseline demographic and clinical characteristics of the patients.
Data are number (%) or mean (SD) unless otherwise indicated.
Characteristic Adalimumab, Infliximab, 
n = 43 n = 48
Sex, F:M 5.1:1 2.7:1
Age, yrs 8.8 (4.4) 10.5 (4.3)
Age at arthritis onset, yrs 3.9 (3.2) 4.8 (3.2)
Range 1.0–15.6 0.6–13.4
Age at uveitis onset, yrs 4.7 (4.2) 4.9 (3.3)
Range 1.0–18.0 0.9–15.0
Time interval arthritis/uveitis, mo 18.5 (24.9) 27.2 (33.1)
Range 0.0–120.1 0.0–137.7
Uveitis duration, yrs 4.1 (3.5) 5.5 (4.7)
Range 0.0–15.9 0.3–18.0
Previous treatments
Methotrexate 35* (81.4) 41 (85.4)
Cyclosporine A 3 (7.0) 10 (20.8)
Corticosteroid dependency 17 (39.5) 18 (37.5)
* Five patients in this group were intolerant to methotrexate and were not
considered because of the very short (< 3 weeks) treatment duration.
Table 2. Change of uveitis course after treatment with anti-tumor necrosis
factor agents. Data are number (%) unless otherwise indicated.
Posttreatment Uveitis Course
Pretreatment Uveitis Course Chronic Recurrent Remission
Adalimumab, n = 43
Chronic, n = 26 3 (11.5) 6 (23.1) 17 (65.4)
Recurrent, n = 17 0 (0.0) 5 (29.4) 12 (70.6)
Overall 3 (7) 11 (25.6) 29 (67.4)†
Infliximab, n = 42
Chronic, n = 30 7 (23.3) 10 (33.3) 13 (43.3)
Recurrent, n = 12 0 (0.0) 7 (58.3) 5 (41.7)
Overall 7 (16.7) 17 (40.5) 18 (42.8)†
Overall, n = 85
Chronic, n = 56 10 (17.8) 16 (28.6) 30 (53.6)
Recurrent, n = 29 0 (0.0) 12 (41.4) 17 (58.6)
Overall 10 (11.8) 28 (32.9) 47 (55.3)
† p < 0.05.
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DISCUSSION
The treatment of JIA-AU varies considerably in type and
timing and frequently does not adequately control intra -
ocular inflammation; side effects and poor visual outcome
are still quite common6,7,8,9. Anti-TNF-α agents have
recently been indicated as possible therapeutic options to
treat AU and to prevent ocular complications10,11,12.
We report the safety and efficacy results of the first year
of anti-TNF-α treatment in a large cohort of patients with
refractory JIA-AU with data recorded in the NIR. This
cohort represents the largest and most homogeneous group
of pediatric patients with AU treated with anti-TNF-α
reported to date. It includes data for patients with oligo -
articular JIA, the subtype more prone to develop refractory
uveitis. Other subtypes, such as polyarticular, psoriatic, and
enthesitis-related JIA, are rarely affected by severe-course
uveitis by themselves, probably because they receive
TNF-blocker treatment early in the disease course to control
the arthritis.
At the start of anti-TNF-α treatment, one-third of the
patients already had a complicated uveitis and as many as
two-thirds had a chronic (severe) uveitis course. To assess
the efficacy of anti-TNF-α agents, we analyzed changes in
the uveitis course in terms of number of uveitis flares
compared with the previous year, and changes in ocular
complications.
Both IFX and ADA were found to be effective in
JIA-AU, as 88.2% of the patients improved; half achieved
remission and one-third maintained a recurrent course.
Indeed, the rate of chronic-severe disease course dropped
from 65.9% to 11.8%. These results confirm some previous
retrospective studies in which ADA was effective in
reducing the ocular inflammation and the recurrence rate in
the majority of JIA patients with longstanding uveitis, which
was poorly responsive to conventional treatments13,14.
Interestingly, in our study the comparison between ADA
and IFX showed better results for ADA, in that the overall
remission rate was 67.4%, versus 42.8% with IFX (p =
0.025). This result is in contrast with another study showing
no difference in the uveitis remission rate between the 2
treatment regimens15, and it demonstrates that ADA is more
efficacious in maintaining remission of uveitis over time.
That study15, however, was different from ours in that it
included a smaller, heterogeneous patient cohort with
different types of uveitis, such as idiopathic, Behçet,
sarcoid, and JIA-related uveitis. These different features
partly explain the diverging results of the 2 studies.
On treatment with anti-TNF agents, ocular complications
improved significantly, as their number decreased from 0.47
to 0.32 per subject. Only 3 patients (2 on IFX and 1 ADA)
experienced new-onset cataract, but as suggested by other
authors, this complication was probably due to previous
prolonged topical corticosteroid treatment16,17. In a retro-
spective case series of 24 children treated with anti-TNF-α
Figure 1. Ocular complications at baseline and after 12 months of treatment with infliximab or
 adalimumab.
Table 3. Adverse events (AE) related to anti-tumor necrosis factor
treatment. Data are number (%) unless otherwise indicated.
Adverse Event Infliximab, n = 48 Adalimumab, n = 43
Major AE 0 0
Minor AE 9 (18.7) 2 (4.7)
Infections 3 0
Upper respiratory tract 1 0
Herpes zoster virus 1 0
Urinary tract 1 0
Infusion reactions 3 0
Systemic symptoms 3 2
Headache 2 0
Irritability 1 0
Urticarial rash 0 1
Prolonged menses 0 1
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agents, a significant rate (17%) of worsening of preexisting
glaucoma occurred during IFX treatment7. In general, while
the improvement in number and severity of some ocular
complications, such as glaucoma or cataract, is usually
related to treatment, worsening can be a reflection of
existing damage from previous inflammation or steroid
treatment and is not necessarily a result of ongoing
 inflammation.
Of note, the frequency of vitreitis and CME decreased
significantly during the first year of treatment. Similar
results have been reported in a series of 19 patients,
including adults, treated with ADA for 1 year18. In that
study, CME (detected by OCT in 86% of the eyes at
baseline) resolved completely in 54.5% of subjects.
Similarly, we observed resolution of CME in 50% of the
patients in our study, although this complication was present
in only 6.
Recent studies provide preliminary evidence that, in
refractory uveitis with a loss of initial clinical response to a
biologic agent, switching to another agent can restore the
control of intraocular inflammation19,20. In a recent case
series, 7 patients with refractory uveitis switched therapy
from IFX to ADA and achieved remission19. Indeed, this
change may offer several adjunctive advantages, such as
easier administration, better patient compliance, and lower
rate of AE20. In our study, 6 patients switched from IFX to
ADA because of infusion reactions, intolerance, or difficult
compliance. However, because of the short followup after
switching, it was not possible to evaluate the real signifi-
cance of this change. The safety profile of both anti-TNF-α
agents was acceptable, as only 8.8% developed minor AE.
ADA was better tolerated, as only 1 case of transient
urticarial rash and 1 of prolonged menses were observed.
Conversely, a study of 26 patients with JIA who were treated
with ADA for arthritis reported a higher rate of AE (26.9%),
mostly respiratory tract infections21. Also in contrast with
previous studies14, we were surprised that local reactions to
ADA were reported rarely by our patients. The reason for
this could be 2-fold; in most of the patients, ADA injection
was preceded by the application of anesthetic cream
(EMLA). Second, the high motivation to perform the
treatment for a risky complication and the high expectation
from the parents may have reduced the psychological effect
of possible local reactions, which were probably reported
less frequently.
Almost one-fifth of our patients receiving IFX developed
1 or more AE, which included infections (3 cases), flu-like
symptoms (3 cases), and infusion reactions (3 cases).
Similarly, a retrospective study on a series of 20 children
showed a comparable rate of AE (15%), mostly infections
and infusion reactions22.
The autoantibody testing revealed anti-DNA antibodies
in 3 patients (2 on IFX, 1 ADA), but no lupus-like
symptoms were reported. This confirms data from a recent
study that autoantibody screening tests in pediatric patients
treated with anti-TNF agents were mostly negative or
nonspecific, suggesting a less frequent screening program23.
Data from the NIR show that IFX and ADA appear to be
effective and safe for treatment of refractory JIA-related
uveitis, with a better performance of ADA in the medium
term. Continuing collection of data from this registry,
involving pediatric rheumatologists and ophthalmologists,
will provide further information on the longterm efficacy
and safety of these and other biologic agents.
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Safety and Efficacy of Infliximab and Adalimumab for
Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year
Followup Data from the Italian Registry
Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki
I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R,
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L, La Torre F, Vittadello F, Martini G, Zulian F. Safety and
efficacy of infliximab and adalimumab for refractory uveitis
in juvenile idiopathic arthritis: 1-year followup data from the
Italian Registry. J Rheumatol 2013;40:74-9. The correct af-
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